QYUNS-B (02509) Rises Over 3% Following Windward Bio's Completion of $165 Million Crossover Financing to Advance WIN027 Clinical Study

Stock News05-11

QYUNS-B (02509) saw its stock price increase by more than 3%. As of the latest update, the share price rose by 3.47% to HK$17.28, with a trading volume of HK$4.2084 million.

On May 8, according to an announcement from the company, QYUNS-B announced the recent completion of a $165 million crossover financing round. The proceeds will be used to advance the development of candidate drugs, including WIN027 (QYUNS-B's R&D code: QX027N) and WIN378.

Since its establishment in January 2025, Windward Bio has raised a cumulative total of $365 million in funding. QYUNS-B entered into a collaboration with Windward Bio regarding QX027N in December 2025.

Currently, WIN027 is in the Phase I clinical research stage, with data readout expected to be completed by the end of 2026. This financing round will support WIN027's planned proof-of-concept studies targeting respiratory and dermatological indications, which are scheduled to commence in the fourth quarter of 2026.

Additionally, Windward Bio's lead project, WIN378, is a next-generation fully human monoclonal antibody targeting TSLP, offering the potential for ultra-long-acting treatment with dosing only twice a year. WIN378 is currently undergoing the Phase II/III POLARIS clinical trial for the treatment of asthma. The Phase II dose-escalation stage of the POLARIS trial has completed patient enrollment, with preliminary data expected to be released in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131632209?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131632209","market":"sh","top_or_hot":-1,"title":"QYUNS-B (02509) Rises Over 3% Following Windward Bio's Completion of $165 Million Crossover Financing to Advance WIN027 Clinical Study","media":"Stock News","content":"<p>QYUNS-B (02509) saw its stock price increase by more than 3%. As of the latest update, the share price rose by 3.47% to HK$17.28, with a trading volume of HK$4.2084 million.</p>\n<p>On May 8, according to an announcement from the company, QYUNS-B announced the recent completion of a $165 million crossover financing round. The proceeds will be used to advance the development of candidate drugs, including WIN027 (QYUNS-B's R&D code: QX027N) and WIN378.</p>\n<p>Since its establishment in January 2025, Windward Bio has raised a cumulative total of $365 million in funding. QYUNS-B entered into a collaboration with Windward Bio regarding QX027N in December 2025.</p>\n<p>Currently, WIN027 is in the Phase I clinical research stage, with data readout expected to be completed by the end of 2026. This financing round will support WIN027's planned proof-of-concept studies targeting respiratory and dermatological indications, which are scheduled to commence in the fourth quarter of 2026.</p>\n<p>Additionally, Windward Bio's lead project, WIN378, is a next-generation fully human monoclonal antibody targeting TSLP, offering the potential for ultra-long-acting treatment with dosing only twice a year. WIN378 is currently undergoing the Phase II/III POLARIS clinical trial for the treatment of asthma. The Phase II dose-escalation stage of the POLARIS trial has completed patient enrollment, with preliminary data expected to be released in the second half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B (02509) Rises Over 3% Following Windward Bio's Completion of $165 Million Crossover Financing to Advance WIN027 Clinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B (02509) Rises Over 3% Following Windward Bio's Completion of $165 Million Crossover Financing to Advance WIN027 Clinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-11 11:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) saw its stock price increase by more than 3%. As of the latest update, the share price rose by 3.47% to HK$17.28, with a trading volume of HK$4.2084 million.</p>\n<p>On May 8, according to an announcement from the company, QYUNS-B announced the recent completion of a $165 million crossover financing round. The proceeds will be used to advance the development of candidate drugs, including WIN027 (QYUNS-B's R&D code: QX027N) and WIN378.</p>\n<p>Since its establishment in January 2025, Windward Bio has raised a cumulative total of $365 million in funding. QYUNS-B entered into a collaboration with Windward Bio regarding QX027N in December 2025.</p>\n<p>Currently, WIN027 is in the Phase I clinical research stage, with data readout expected to be completed by the end of 2026. This financing round will support WIN027's planned proof-of-concept studies targeting respiratory and dermatological indications, which are scheduled to commence in the fourth quarter of 2026.</p>\n<p>Additionally, Windward Bio's lead project, WIN378, is a next-generation fully human monoclonal antibody targeting TSLP, offering the potential for ultra-long-acting treatment with dosing only twice a year. WIN378 is currently undergoing the Phase II/III POLARIS clinical trial for the treatment of asthma. The Phase II dose-escalation stage of the POLARIS trial has completed patient enrollment, with preliminary data expected to be released in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1131632209","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131632209","pubTimestamp":1778470108,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) saw its stock price increase by more than 3%. As of the latest update, the share price rose by 3.47% to HK$17.28, with a trading volume of HK$4.2084 million. On May 8, according to an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","02509":"荃信生物-B"},"translate_title":"Windward Bio完成1.65亿美元交叉融资推进WIN027临床研究后，QYUNS-B(02509)涨超3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02509":1},"content_text":"QYUNS-B (02509) saw its stock price increase by more than 3%. As of the latest update, the share price rose by 3.47% to HK$17.28, with a trading volume of HK$4.2084 million.\nOn May 8, according to an announcement from the company, QYUNS-B announced the recent completion of a $165 million crossover financing round. The proceeds will be used to advance the development of candidate drugs, including WIN027 (QYUNS-B's R&D code: QX027N) and WIN378.\nSince its establishment in January 2025, Windward Bio has raised a cumulative total of $365 million in funding. QYUNS-B entered into a collaboration with Windward Bio regarding QX027N in December 2025.\nCurrently, WIN027 is in the Phase I clinical research stage, with data readout expected to be completed by the end of 2026. This financing round will support WIN027's planned proof-of-concept studies targeting respiratory and dermatological indications, which are scheduled to commence in the fourth quarter of 2026.\nAdditionally, Windward Bio's lead project, WIN378, is a next-generation fully human monoclonal antibody targeting TSLP, offering the potential for ultra-long-acting treatment with dosing only twice a year. WIN378 is currently undergoing the Phase II/III POLARIS clinical trial for the treatment of asthma. The Phase II dose-escalation stage of the POLARIS trial has completed patient enrollment, with preliminary data expected to be released in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131632209","isCrawlerRequest":true}